WO2013014405A3 - Methods of inhibiting inflammation comprising inhibiting cd63 - Google Patents
Methods of inhibiting inflammation comprising inhibiting cd63 Download PDFInfo
- Publication number
- WO2013014405A3 WO2013014405A3 PCT/GB2012/000605 GB2012000605W WO2013014405A3 WO 2013014405 A3 WO2013014405 A3 WO 2013014405A3 GB 2012000605 W GB2012000605 W GB 2012000605W WO 2013014405 A3 WO2013014405 A3 WO 2013014405A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibiting
- reducing
- methods
- inflammation
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
The invention relates to methods of inhibiting inflammation in a system comprising reducing or inhibiting CD63 in said system, wherein said inflammation is IgE-negative. The invention also relates to methods for inhibiting leukocyte recruitment in a system, inhibiting leukocyte rolling in a system, or inhibiting leukocyte extravasation in a system comprising reducing or inhibiting CD63 in said system. The invention also provides a method of reducing P-selectin levels comprising reducing or inhibiting CD63, and a method of reducing P-selectin clustering comprising reducing or inhibiting CD63.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201112718A GB201112718D0 (en) | 2011-07-22 | 2011-07-22 | Methods |
GB1112718.0 | 2011-07-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013014405A2 WO2013014405A2 (en) | 2013-01-31 |
WO2013014405A3 true WO2013014405A3 (en) | 2013-05-30 |
Family
ID=44652232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2012/000605 WO2013014405A2 (en) | 2011-07-22 | 2012-07-20 | Methods |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201112718D0 (en) |
WO (1) | WO2013014405A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017197158A1 (en) * | 2016-05-11 | 2017-11-16 | Leuvas Therapeutics | Blockade of tim-1 pathways and p-selectin pathways in treatment of neuroinflammatory degenerative disease |
US20190388548A1 (en) * | 2018-06-26 | 2019-12-26 | Tzu Chi University | Method for providing ocular neuroprotection or for preventing, treating or alleviating the effects of, an ocular disease associated with retinal ganglion cell death |
EP4210735A1 (en) | 2020-09-10 | 2023-07-19 | Vascular Biogenics Ltd. | Motile sperm domain containing protein 2 antibodies and methods of use thereof |
WO2022208320A1 (en) * | 2021-03-29 | 2022-10-06 | Vascular Biogenics Ltd. | Motile sperm domain containing protein 2, integrin beta2 and cd63 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007117432A2 (en) * | 2006-03-30 | 2007-10-18 | The Regents Of The University Of Michigan | Methods and compositions for modulating angiogenesis and tumor growth |
WO2011029823A1 (en) * | 2009-09-09 | 2011-03-17 | Novartis Ag | Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO2005007695A2 (en) | 2003-07-14 | 2005-01-27 | Beth Israel Deaconess Medical Center, Inc. | Anti-cd63 antibodies and methods of use thereof |
-
2011
- 2011-07-22 GB GB201112718A patent/GB201112718D0/en not_active Ceased
-
2012
- 2012-07-20 WO PCT/GB2012/000605 patent/WO2013014405A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007117432A2 (en) * | 2006-03-30 | 2007-10-18 | The Regents Of The University Of Michigan | Methods and compositions for modulating angiogenesis and tumor growth |
WO2011029823A1 (en) * | 2009-09-09 | 2011-03-17 | Novartis Ag | Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells |
Non-Patent Citations (11)
Title |
---|
BJÖRN PETRI ET AL: "The physiology of leukocyte recruitment: an in vivo perspective.", THE JOURNAL OF IMMUNOLOGY, vol. 180, no. 10, 1 May 2008 (2008-05-01), pages 6439 - 6446, XP055047154, ISSN: 0022-1767 * |
E. L. DOYLE ET AL: "CD63 is an essential cofactor to leukocyte recruitment by endothelial P-selectin", BLOOD, vol. 118, no. 15, 13 October 2011 (2011-10-13), pages 4265 - 4273, XP055046518, ISSN: 0006-4971, DOI: 10.1182/blood-2010-11-321489 * |
HAI-BO WANG ET AL: "P-selectin primes leukocyte integrin activation during inflammation", NATURE IMMUNOLOGY, vol. 8, no. 8, 1 August 2007 (2007-08-01), pages 882 - 892, XP055046717, ISSN: 1529-2908, DOI: 10.1038/ni1491 * |
JOCKERS J J ET AL: "Different expression of adhesion molecules and tetraspanins of monocytes of patients with atopic eczema", ALLERGY, WILEY-BLACKWELL PUBLISHING LTD, UNITED KINGDOM, vol. 61, no. 12, 1 December 2006 (2006-12-01), pages 1419 - 1422, XP009138950, ISSN: 0105-4538, [retrieved on 20060817], DOI: 10.1111/J.1398-9995.2006.01191.X * |
KIMBERLY J. HARRISON-LAVOIE ET AL: "P-Selectin and CD63 Use Different Mechanisms for Delivery to Weibel-Palade Bodies", TRAFFIC, vol. 7, no. 6, 1 June 2006 (2006-06-01), pages 647 - 662, XP055046522, ISSN: 1398-9219, DOI: 10.1111/j.1600-0854.2006.00415.x * |
L. KALLQUIST ET AL: "The tetraspanin CD63 is involved in granule targeting of neutrophil elastase", BLOOD, vol. 112, no. 8, 15 October 2008 (2008-10-15), pages 3444 - 3454, XP055046526, ISSN: 0006-4971, DOI: 10.1182/blood-2007-10-116285 * |
MAYADAS T N ET AL: "Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice", CELL, CELL PRESS, US, vol. 74, no. 3, 13 August 1993 (1993-08-13), pages 541 - 554, XP023913412, ISSN: 0092-8674, [retrieved on 19930813], DOI: 10.1016/0092-8674(93)80055-J * |
MCKENZIE MARCUS E ET AL: "Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets", BLOOD COAGULATION & FIBRINOLYSIS, RAPID COMMUNICATIONS, OXFORD, OXFORD, GB, vol. 14, no. 3, 1 April 2003 (2003-04-01), pages 249 - 253, XP008158590, ISSN: 0957-5235 * |
R. S. SCOTLAND: "C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 102, no. 40, 1 January 2005 (2005-01-01), pages 14452 - 14457, XP055046654, ISSN: 0027-8424, DOI: 10.1073/pnas.0504961102 * |
SZEKANECZ Z ET AL: "Therapeutic inhibition of leukocyte recruitment in inflammatory diseases", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 4, no. 4, 1 August 2004 (2004-08-01), pages 423 - 428, XP008090734, ISSN: 1471-4892 * |
ZSUZSA SIMON ET AL: "Protein phosphatase inhibitor calyculin - A modulates activation markers in TRAP-stimulated human platelets", PLATELETS, TAYLOR AND FRANCIS GROUP, EDINBURGH, vol. 21, no. 7, 1 January 2010 (2010-01-01), pages 555 - 562, XP008158600, ISSN: 0953-7104 * |
Also Published As
Publication number | Publication date |
---|---|
WO2013014405A2 (en) | 2013-01-31 |
GB201112718D0 (en) | 2011-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2705419A4 (en) | Database system and method | |
WO2012106735A3 (en) | Plasma-assisted skin treatment | |
IL227426A0 (en) | System, method, and article to prompt behavior change | |
EP2883172A4 (en) | High performance real-time relational database system and methods for using same | |
EP2774380A4 (en) | Method and system for stereo gaze tracking | |
IL216056A0 (en) | Combined database system and method | |
EP2775955B8 (en) | Milling block, method for producing partial or total prostheses and milling block system | |
EP2739224A4 (en) | System and method for cold plasma therapy | |
EP3050994A4 (en) | Non-quenched and tempered steel and manufacturing method therefor | |
EP3050993A4 (en) | Non-quenched and tempered steel and manufacturing method therefor | |
WO2012129341A3 (en) | Disease detection in plants | |
SG11201404555WA (en) | Multi-source, multi-dimensional, cross-entity, multimedia database platform apparatuses, methods and systems | |
WO2012116010A3 (en) | Antibiotic tolerance inhibitors | |
EP2690188A4 (en) | Austenite system alloy pipe and manufacturing method thereof | |
EP2789704A4 (en) | Bearing components, rolling bearing, and methods for producing same | |
EP3050995A4 (en) | Non-quenched and tempered steel and manufacturing method therefor | |
EP2665147A4 (en) | High-pressure equipment system for rolling stock, and rolling stock | |
WO2013010034A3 (en) | Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers | |
MX2012013740A (en) | Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin. | |
WO2013014405A3 (en) | Methods of inhibiting inflammation comprising inhibiting cd63 | |
EP3050991A4 (en) | Non-quenched and tempered steel and manufacturing method therefor | |
SG10201705091YA (en) | METHOD FOR PRODUCING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID DERIVATIVE, AND METHOD FOR PURIFYING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID | |
GB2495825B (en) | Filters, systems and methods for reducing can velocity | |
HK1219269A1 (en) | Compound and method for producing same, as well as method for producing oseltamivir phosphate | |
ZA201305380B (en) | Method of and system for sporting event betting |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12753157 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12753157 Country of ref document: EP Kind code of ref document: A2 |